Faculty, Staff and Student Publications

Language

English

Publication Date

2-1-2025

Journal

American Journal of Hematology

DOI

10.1002/ajh.27561

PMID

39718824

PMCID

PMC12777743

PubMedCentral® Posted Date

1-8-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

Patients who develop acute myeloid leukemia (AML) after having received treatment for myelodysplastic syndrome (MDS) or related conditions have particularly poor outcomes. This study analyzed adult patients with newly diagnosed AML who previously had MDS, chronic myelomonocytic leukemia (CMML), or MDS/myeloproliferative neoplasm (MPN) overlap syndrome, and who had received hypomethylating agents, chemotherapy, and/or allogeneic stem cell transplantation (HSCT) for these antecedent disorders. From January 2012 to August 2023, we included 673 patients with a median age of 70 years (range, 19-94); 536 (80%) had transformed from MDS, and the remainder from CMML or MDS-MPN. Additionally, 149 patients (22%) had prior therapy for nonmyeloid malignancies. Among 497 evaluable patients, 289 (58%) had adverse-risk (AR) cytogenetics, 34% had TP53 mutation/s, and 71% were classified as AR by the ELN 2017 criteria. Most patients (67%) received low-intensity therapy (LIT) for AML, and 27% were treated with venetoclax. The overall response rate was 37%, and venetoclax improved the odds of response (OR = 2.5, 95% CI 1.6-3.7) in LIT-treated patients. At a median follow-up of 43 months, the median relapse-free survival (RFS) and overall survival (OS) were 4.6 and 4.8 months, respectively. Multivariate analysis showed that prior therapy for nonmyeloid disorders (HR = 1.30), ≥ 2 lines of therapy for antecedent myeloid disorders (HR = 1.23), and ELN AR risk (HR = 1.47) increased the hazards of death, while HSCT (HR = 0.50) was beneficial and validated on gradient-boosted regression. TS-AML is associated with poor outcomes irrespective of AML genomics and treatment, highlighting the need for its inclusion as an independent AR category for accurate prognostication and clinical trial reporting.

Keywords

Humans, Leukemia, Myeloid, Acute, Aged, Middle Aged, Male, Female, Adult, Aged, 80 and over, Prognosis, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation, Young Adult, Neoplasms, Second Primary, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Treatment Outcome, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Secondary Acute Myeloid Leukemia, Myelodysplastic syndrome, Venetoclax, TP53, Stem Cell Transplantation

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.